Michel Goldman, MD, PhD, was the Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI) from 2009 to 2014. With a budget of 2 billions € provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he launched and monitored 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer’s dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety.
Professor of Immunology at the Université Libre de Bruxelles, Belgium, Michel Goldman was previously the Head of the Department of immunology-hematology-transfusion at the Hôpital Erasme (Brussels) and the Director of the ULB Institute for Medical Immunology . He currently builds research and education programs on collaborative innovation in medicine.
Michel Goldman’s scientific achievements resulted in more than 400 articles in peer-reviewed journals and he was recognised as ISI Highly Cited Scientist in 2006 by the Thomson Institute for Scientific Information. In 2000 he received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Fonds National de la Recherche Scientifique (Belgium) and he held in 2001 the Spinoza chair at the University of Amsterdam, the Netherlands. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II, France.